Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old)
NCT02619630
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
275
Enrollment
OTHER
Sponsor class
Conditions
T-cell Adult Acute Lymphoblastic Leukemia
Interventions
DRUG:
nelarabine
Sponsor
Assistance Publique - Hôpitaux de Paris